SS-31 — Research Overview
Chemical Name: D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2 Also Known As: SS-31, elamipretide, MTP-131, Bendavia IUPAC Name: (D-Arg)-(2′,6′-dimethyl-L-Tyr)-(L-Lys)-(L-Phe)-NH2 Abbreviation Origin: “SS” stands for Szeto-Schiller, honoring the two researchers — Hazel Szeto (Cornell/Weill Cornell Medicine) and Peter Schiller (Institut de recherches cliniques de Montréal) — in whose opioid receptor research program this class of compounds was serendipitously discovered. “31” designates its position in the original series of Szeto-Schiller (SS) peptides. Structure: Synthetic tetrapeptide with an alternating aromatic-cationic amino acid motif: D-arginine (D-Arg) — 2′,6′-dimethyltyrosine (Dmt) — lysine (Lys) — phenylalanine (Phe), C-terminally amidated (-NH2). The two positively charged residues (D-Arg, Lys) and two aromatic residues (Dmt, Phe) alternate in a pattern that simultaneously enables electrostatic attraction to the negatively charged inner mitochondrial membrane and membrane penetration through hydrophobic interactions. FDA Regulatory Status: FDA accelerated approval granted September 19, 2025, for treatment of Barth syndrome (X-linked cardioskeletal myopathy) — making elamipretide/SS-31 the first approved disease-specific treatment for this condition and the first FDA-approved mitochondria-targeted peptide therapeutic. Brand Name (Post-Approval): RAXONE was the name under consideration during development; the approved brand name should be confirmed via FDA labeling at time of prescribing. Developer: Stealth BioTherapeutics (Newton, Massachusetts); foundational science from Hazel Szeto’s laboratory at Weill Cornell Medicine. Discovery: SS peptides were discovered serendipitously while Szeto and Schiller were studying opioid receptors — they observed that certain amphipathic peptides with alternating aromatic-cationic sequences accumulated preferentially in mitochondria. This fortuitous discovery established the framework for mitochondria-targeted peptide therapeutics. WADA Status: Not specifically listed on the WADA prohibited list as of this compilation. Category: Mitochondria-targeted tetrapeptide / cardiolipin-binding membrane stabilizer / inner mitochondrial membrane (IMM) therapeutic / electron transport chain optimizer / FDA-accelerated-approval pharmaceutical for Barth syndrome / research tool for mitochondrial dysfunction biology
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption outside of the specific FDA-approved pharmaceutical indication described above (Barth syndrome, approved pharmaceutical formulation). The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is SS-31?
SS-31 is a synthetic tetrapeptide with a structural architecture — alternating aromatic and positively charged amino acids — that enables two simultaneous physical properties that together constitute its mechanism of action: cell membrane permeability and selective concentration in the inner mitochondrial membrane. This structural design allows SS-31 to accumulate at the cardiolipin-rich inner mitochondrial membrane at concentrations orders of magnitude higher than in the cytoplasm, without requiring active transport machinery or membrane potential-dependent uptake. The discovery of this targeting behavior was serendipitous, emerging from opioid receptor research rather than rational drug design — one of the more remarkable serendipitous discoveries in peptide science.
SS-31’s pharmacological significance lies at the intersection of two of the most active areas in biomedical research: mitochondrial biology and aging. Mitochondria are not merely ATP-producing organelles — they are central regulators of cellular life and death, calcium homeostasis, reactive oxygen species (ROS) balance, and the signaling networks that coordinate stress responses, apoptosis, and inflammatory activation. Mitochondrial dysfunction has been identified as a common upstream driver in a remarkable breadth of conditions including age-related cardiac dysfunction, heart failure, neurodegenerative diseases, ischemia-reperfusion injury, inherited mitochondrial diseases, kidney disease, metabolic syndrome, and the general aging process. A compound that specifically targets the inner mitochondrial membrane — where electron transport, ATP synthesis, and ROS generation all occur — and improves membrane architecture and function from within represents a genuinely novel pharmacological approach.
The September 2025 FDA accelerated approval of elamipretide for Barth syndrome represents the clinical validation of this approach in a genetically defined model of inner mitochondrial membrane pathology. Barth syndrome is caused by mutations in the TAFAZZIN gene, which encodes an enzyme required for cardiolipin remodeling — meaning Barth syndrome is mechanistically the most direct possible model of the cardiolipin dysregulation that SS-31 is designed to address. The approval establishes SS-31 as the first clinically validated cardiolipin-targeted therapeutic in history.
Cardiolipin — The Essential Biology
Understanding SS-31 requires understanding cardiolipin — the mitochondria-specific phospholipid that is its primary molecular target.
Cardiolipin (CL) is a unique anionic phospholipid that carries two phosphate head groups and four fatty acid chains — making it a doubly negatively charged “double phospholipid” unlike any other membrane lipid. In eukaryotic cells, cardiolipin is almost exclusively localized on the inner mitochondrial membrane (IMM), where it constitutes approximately 15-20% of total lipid content. This IMM-specificity makes cardiolipin a perfect molecular address for targeted drug delivery to this specific membrane.
Cardiolipin serves multiple non-redundant structural and functional roles in the IMM. It is essential for the structural integrity and curvature of cristae — the invaginations of the IMM where the respiratory chain complexes are physically located. Cardiolipin stabilizes the supercomplexes (respirasomes) formed by respiratory chain Complexes I, III, and IV — the organizational architecture that maximizes electron transfer efficiency and minimizes electron leakage. Cardiolipin is required for the activity of the adenine nucleotide translocator (ANT), which exchanges ADP for ATP across the IMM — making it essential for the actual export of synthesized ATP to the cytoplasm. Cardiolipin also stabilizes cytochrome c in its electron-transfer configuration at the IMM and suppresses its peroxidase activity, which otherwise generates lipid peroxides.
When cardiolipin is damaged — by oxidative modification (cardiolipin peroxidation), by enzymatic remodeling defects (as in Barth syndrome), or by aging-related compositional changes — cristae collapse, respiratory complex supercomplexes disassemble, electron transport efficiency falls, ROS generation increases, ATP production decreases, and cytochrome c gains pathological peroxidase activity that initiates apoptotic cascades. This cardiolipin damage signature is consistently found in heart failure, ischemia-reperfusion injury, skeletal muscle aging, neurodegeneration, and inherited mitochondrial diseases — which is why SS-31’s cardiolipin-stabilizing mechanism is relevant across such a broad disease landscape.
Mechanism of Action
Selective inner mitochondrial membrane targeting through electrostatic-aromatic architecture: SS-31’s ability to accumulate at the IMM without requiring active transport is its defining pharmacological property. Two mechanisms operate simultaneously. The positively charged D-Arg and Lys residues are electrostatically attracted to the highly negatively charged cardiolipin-rich IMM. The aromatic residues (Dmt, Phe) simultaneously shield the positive charges from the aqueous phase through π-orbital electron delocalization, enabling the peptide to permeate cell membranes without triggering transport resistance mechanisms that would otherwise block cationic peptides. The amphipathic structure — hydrophilic cationic residues alternating with hydrophobic aromatic residues — enables interaction with both the lipid bilayer (through aromatic insertion) and the aqueous phase (through cationic anchoring). The net result is selective 1,000-fold or greater concentration of SS-31 at the IMM compared to the bulk cytoplasm.
Cardiolipin binding — the primary molecular interaction: SS-31 partitions into the IMM interfacial region with binding affinity directly related to membrane surface charge — meaning cardiolipin content directly determines SS-31’s binding density at any given membrane. Binding studies using biophysical and computational approaches confirmed specific, saturable, calcium-dependent binding to cardiolipin-containing membranes. At mitochondrial cardiolipin concentrations, each SS-31 molecule associates with approximately 1.4-1.5 dianionic cardiolipin lipids — a defined stoichiometric interaction rather than nonspecific adsorption.
Cristae structure stabilization: By binding cardiolipin at the IMM, SS-31 physically stabilizes cristae curvature and morphology. Cardiolipin’s unique molecular geometry (the cone shape of its four acyl chains converging on two phosphate head groups) contributes to the high membrane curvature at cristae junctions. When cardiolipin is damaged or depleted, cristae collapse from their tight curved morphology to flattened, disorganized forms that cannot support the spatial organization of respiratory supercomplexes. SS-31 binding stabilizes cardiolipin-dependent cristae curvature, restoring the physical architecture on which respiratory complex superassembly depends.
Respiratory complex optimization and ETC efficiency: Chemical cross-linking with mass spectrometry (PNAS 2020) directly identified SS-31’s protein interactors in mitochondria as falling into two groups: proteins involved in ATP production through the oxidative phosphorylation pathway (Complex I, Complex III, Complex IV, ATP synthase, and ANT) and proteins involved in 2-oxoglutarate metabolic processes. All identified SS-31 protein interactors were known cardiolipin-binding proteins — establishing that SS-31’s protein interactions occur through the cardiolipin that bridges SS-31 to these complexes rather than through direct protein binding. This cardiolipin-mediated interaction with the entire OXPHOS machinery explains how SS-31 enhances electron transport, reduces electron leak, and increases ATP synthesis simultaneously.
Cytochrome c peroxidase inhibition: Cardiolipin normally holds cytochrome c in an electron-transfer configuration at the IMM where it shuttles electrons from Complex III to Complex IV. When cardiolipin is peroxidized (oxidized by ROS), cytochrome c gains aberrant peroxidase activity — it uses the peroxidized cardiolipin as substrate to generate lipid peroxides that damage membranes and initiate apoptosis. SS-31 binding to cardiolipin suppresses cytochrome c’s peroxidase activity, interrupting this lipid peroxidation cascade and blocking the apoptotic signal that damaged cardiolipin would otherwise generate.
ROS reduction through electron leak suppression rather than scavenging: Initial characterization of SS-31 emphasized the antioxidant activity of its Dmt residue — dimethyltyrosine can scavenge oxygen radicals through tyrosine radical coupling to di-tyrosine. However, subsequent research established that antioxidant scavenging is not the primary mechanism: SS-31 analogs lacking the Dmt antioxidant motif (such as SS-20) retain substantial protective activity, and stoichiometric scavenging cannot account for the magnitude of ROS reduction observed. The primary mechanism of ROS reduction is the suppression of electron leak from the ETC through improved cristae architecture and respiratory complex superassembly — less electron escape from the ETC means less superoxide generation at its source rather than downstream scavenging of superoxide already produced.
ADP sensitivity restoration through ANT interaction: A 2023 study directly demonstrated that SS-31 (elamipretide) improves ADP sensitivity in aged muscle mitochondria — the capacity to ramp up ATP synthesis in response to ADP demand, which is severely impaired in aging. Chemical cross-linking confirmed direct SS-31 interaction with ANT and ATP synthase. SS-31 treatment decreased glutathionylation (an oxidative modification) of ANT in aged mitochondria — a specific mechanism by which oxidative stress impairs ANT function in aging. By restoring ANT redox state and function, SS-31 improves the mitochondria’s ability to respond to cellular energy demands.
Published Research
Study 1 — Foundational Protein Interactome: SS-31 Directly Interacts with OXPHOS Machinery Through Cardiolipin
Authors: Mitchell W, Ng EA, Tamucci JD et al. Year: 2020 Journal: Proceedings of the National Academy of Sciences (PNAS) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/
This landmark PNAS study applied chemical cross-linking with mass spectrometry to directly map SS-31’s protein interaction landscape in mitochondria — providing the first comprehensive molecular evidence for how SS-31’s cardiolipin interaction translates into functional effects on OXPHOS machinery.
SS-31-interacting proteins fell into two functional groups: proteins involved in ATP production through the OXPHOS pathway (Complex I subunits, Complex III, Complex IV/cytochrome c oxidase, ATP synthase, and ANT) and proteins involved in 2-oxoglutarate metabolism and signaling. All identified interactors were known cardiolipin binders — establishing that SS-31 engages the OXPHOS machinery through cardiolipin bridging rather than direct peptide-protein binding.
This protein interaction landscape provides a mechanistic framework explaining how a tetrapeptide acting at the IMM can simultaneously improve electron transport, reduce electron leak, and increase ATP synthesis — by stabilizing the cardiolipin-dependent protein-lipid organization of the entire respiratory machinery rather than targeting a single molecular step.
The study conclusively established that SS-31 is not primarily a simple antioxidant but a structural organizer of the inner mitochondrial membrane’s lipid-protein architecture — a mechanistic reframing of fundamental importance for interpreting the broad therapeutic effects observed across disease models.
Study 2 — Late-Life Reversal of Cardiac Aging: SS-31 Reverses Cardiac Diastolic Dysfunction in Old Mice
Authors: Chiao YA, Zhang H, Sweetwyne M et al. (University of Washington Marcinek laboratory) Year: 2020 Journal: eLife Full text: https://elifesciences.org/articles/55513
This eLife study addressed a critical translational question: can SS-31 initiated in later life reverse pre-existing mitochondrial and cardiac dysfunction, rather than only preventing it? The answer was yes — with important mechanistic characterization.
8-week subcutaneous SS-31 treatment of old mice (approximately 24 months of age — equivalent to approximately 70-75 human years) substantially reversed diastolic dysfunction — a hallmark of cardiac aging in both mice and humans that in clinical practice contributes to heart failure with preserved ejection fraction (HFpEF), a condition for which few effective treatments exist.
SS-31 normalized the increase in proton leak (a measure of mitochondrial inner membrane integrity) in cardiomyocytes from old mice, reduced mitochondrial ROS production, reduced protein oxidation, and shifted cardiac protein thiol redox state toward the more reduced (less oxidized) state characteristic of young hearts.
Improved diastolic function was concordant with increased phosphorylation of cardiac myosin binding protein C Ser282 (cMyBP-C S282) — a phosphorylation event that regulates cardiac muscle relaxation kinetics and is deficient in aging hearts and heart failure with preserved ejection fraction.
Critically, late-life viral expression of mitochondrial-targeted catalase (mCAT, a genetically encoded mitochondrial antioxidant) produced similar functional benefits in old mice, and SS-31 did not improve cardiac function of old mCAT mice — directly demonstrating that normalizing mitochondrial oxidative stress is the overlapping mechanism of both interventions. This convergent evidence implicated mitochondrial ROS as a causal driver of cardiac aging that SS-31 pharmacologically addresses.
The authors concluded that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction — a conclusion with profound implications for therapeutic intervention in aging populations.
Study 3 — Barth Syndrome Phase 2/3 RCT and Open-Label Extension: Human Clinical Evidence
Authors: Thompson WR, Hornby B, Manuel R et al. Year: 2021 Journal: Genetics in Medicine PMID: 33077895 Full text: https://www.nature.com/articles/s41436-020-01006-8
This Phase 2/3 randomized double-blind placebo-controlled crossover trial in patients with Barth syndrome (BTHS) — followed by an open-label extension — was the primary clinical evidence supporting elamipretide’s September 2025 FDA accelerated approval. Barth syndrome is caused by TAFAZZIN mutations that disrupt cardiolipin remodeling, making it the most direct human genetic model of the cardiolipin dysfunction that SS-31 targets.
12 subjects with genetically confirmed BTHS were randomized to 40 mg per day elamipretide or placebo subcutaneously for 12 weeks in a crossover design. Primary endpoints were 6-minute walk test (6MWT) improvement and BTHS Symptom Assessment (BTHS-SA) scale improvement.
In Part 1 (12-week crossover), neither primary endpoint achieved statistical significance — an important honest finding reflecting the limitations of the short treatment duration and small sample size in this ultra-rare disease. However, the results trended in the expected direction.
In Part 2 (open-label extension, 10 subjects continuing to 36 weeks): the 6MWT improved by a mean of 60.5 meters at week 12 (16% increase, P equal to 0.02) and 95.9 meters at week 36 (25% improvement, P equal to 0.02). Handheld dynamometry muscle strength improved by 37.9 newtons at week 12 (30%, P equal to 0.003) and 56.0 newtons at week 36 (42%, P equal to 0.001). Significant improvements were also observed in BTHS-SA total fatigue, Patient Global Impression of symptoms, and cardiac parameters.
The pattern — with effects strengthening substantially over time rather than plateauing — suggests that SS-31’s mechanism of action involves gradual restoration of mitochondrial structural integrity and cardiolipin normalization rather than acute pharmacological effect, requiring extended treatment duration for full therapeutic benefit. This time-dependency is mechanistically consistent with the structural nature of the cardiolipin-stabilization mechanism.
A subsequent 168-week open-label extension study documented sustained improvements in 6MWT, fatigue, cardiac stroke volume (SV), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and MLCL/CL ratio values — demonstrating durable long-term benefit with continued elamipretide therapy.
Study 4 — ADP Sensitivity and ANT: Mechanistic Basis for Aging-Impaired Energy Response
Authors: Campbell MD et al. (Marcinek laboratory) Year: 2023 Journal: Referenced via PMID: 37462785
This study directly characterized how SS-31 restores mitochondrial energy responsiveness in aged muscle — one of the most practically important mechanistic demonstrations of SS-31’s anti-aging effects.
ADP sensitivity — the ability of mitochondria to ramp up ATP production when ADP supply increases during energy demand — is severely impaired in aged skeletal muscle mitochondria. This impaired ADP sensitivity means that aged mitochondria cannot efficiently meet increased energy demands during exercise or stress, contributing to exercise intolerance, fatigue, and functional decline.
Chemical cross-linking confirmed direct SS-31 interactions with ANT and ATP synthase — two proteins central to ATP production and transport. SS-31 treatment decreased glutathionylation of ANT in aged mitochondria — reversing the oxidative modification that impairs ANT function and ADP/ATP exchange efficiency.
SS-31 improved ADP sensitivity to levels comparable to young mitochondria in aged muscle — demonstrating a functional restoration of the energy-responsiveness that aging specifically impairs. This improvement was observed with both acute and chronic SS-31 treatment, establishing that the ADP sensitivity benefit is accessible even at an advanced age.
The mechanistic sequence demonstrated is: aging → increased ROS → ANT glutathionylation → impaired ADP/ATP exchange → reduced ADP sensitivity → reduced ATP production capacity. SS-31 → cardiolipin stabilization → reduced mitochondrial ROS → reduced ANT glutathionylation → restored ADP sensitivity → improved ATP production capacity under demand.
Study 5 — Primary Mitochondrial Myopathy: MMPOWER-2 Crossover Trial
Authors: Researchers in the MMPOWER program (Neurology journal, published 2023) Journal: Neurology Full text: https://www.neurology.org/doi/10.1212/WNL.0000000000207402
The MMPOWER-2 study evaluated elamipretide in 30 participants with genetically confirmed primary mitochondrial myopathy (PMM) — a genetically heterogeneous group of inherited mitochondrial diseases characterized by progressive muscle weakness and exercise intolerance due to mitochondrial OXPHOS dysfunction.
Participants were randomized to 40 mg/day subcutaneous elamipretide or placebo for 4 weeks each in a crossover design. The primary endpoint — 6MWT distance — showed a 19.8 meter improvement with elamipretide versus placebo (P equal to 0.0833) — not reaching the pre-specified 0.05 significance threshold.
Secondary fatigue endpoints showed statistically significant improvements: elamipretide participants reported significantly less fatigue (Primary Mitochondrial Myopathy Symptom Assessment Total Fatigue, P equal to 0.0006) and fewer muscle complaints during activities compared to placebo — clinically meaningful patient-reported outcomes that the 6MWT did not capture.
MMPOWER-3, the subsequent Phase 3 trial in PMM, demonstrated that effort-dependent endpoints are particularly challenging in this heterogeneous population and underscored the importance of trial design considerations for mitochondrial disease research. The fatigue benefit, while not accompanied by the 6MWT improvement hoped for, confirmed that elamipretide produces detectable symptomatic benefit in PMM.
Study 6 — Reversing Cardiac Aging: Mechanistic and Structural Evidence
Authors: Multiple groups including Szeto HH, Birk AV, Dai DF et al. Year: Multiple publications 2013-2020 Referenced via: eLife 2020 (PMID 32628893) and multiple companion publications
The mechanistic evidence that SS-31 interacts with cardiolipin to re-energize ischemic mitochondria, restore cristae architecture, and improve electron transport was established through a series of landmark mechanistic studies from the Szeto and Birk laboratories.
Birk et al. (2013) established that SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin — directly demonstrating the cardiolipin interaction as the primary mechanism and showing that this interaction restored mitochondrial membrane potential, electron transport, and ATP synthesis following ischemia.
Structural studies confirmed that SS-31 binds the interfacial region of cardiolipin-containing membranes with high affinity and density, modulates IMM surface electrostatics, and that these physical membrane changes translate into stabilized cristae morphology and improved respiratory complex organization.
Dog heart failure models treated with 3 months of elamipretide showed significant improvements in stroke volume, ejection fraction, cardiac output, and cardiac index, alongside decreased LVEDP and systemic vascular resistance — demonstrating that cardiolipin-targeted mitochondrial protection translates to substantial whole-organ cardiac functional improvement in a clinically relevant large animal model.
The SS Peptide Family and SS-31’s Position
SS-31 is the lead compound in the Szeto-Schiller (SS) peptide family, but it is important to understand it within the broader family context. SS-20 (D-Phe-Dmt-D-Lys-Phe-NH2) lacks the Dmt antioxidant residue that SS-31 contains but retains substantial activity in multiple models — establishing that antioxidant scavenging is not the primary mechanism. SS-02 (D-Arg-Tyr-Lys-Phe-NH2) differs minimally but shows different potency profiles. The structural requirements for SS peptide activity — the alternating aromatic-cationic pattern, the amphipathic character, the C-terminal amidation — have been systematically characterized to establish structure-activity relationships that inform both mechanism understanding and analog development.
Clinical Applications Beyond Barth Syndrome
While Barth syndrome represents the first FDA-approved indication, the clinical research program for elamipretide has extended across multiple conditions characterized by mitochondrial dysfunction:
Heart failure with reduced ejection fraction: Phase 2 trials in systolic heart failure demonstrated improvements in cardiac parameters. The STRIVE-HF program evaluated elamipretide as a disease-modifying treatment for heart failure.
Ischemia-reperfusion injury: STEMI (acute myocardial infarction) trials evaluated elamipretide administered during PCI to protect ischemic myocardium. The EMBRACE STEMI trial did not demonstrate a reduction in myocardial infarct size as assessed by CK-MB AUC at 72 hours — an important negative result with interpretive implications regarding the timing and duration of ischemic injury treatment required.
Atherosclerotic renal artery stenosis: Phase 2a study demonstrated that elamipretide plus stent revascularization improved renal function, oxygenation, and renal blood flow compared to revascularization alone — suggesting mitochondrial protection as a meaningful component of renal recovery from chronic ischemia.
Age-related macular degeneration (AMD): The ReCLAIM study evaluated elamipretide in patients over 55 with dry AMD — a condition in which photoreceptor mitochondrial dysfunction is a central pathological mechanism. The preclinical basis for this application (prevention of vision loss in diabetic mouse models) is strong.
Skeletal muscle aging and sarcopenia: Multiple preclinical studies demonstrated improved skeletal muscle ATP production, exercise tolerance, and mitochondrial function in aged mice. A randomized trial in older adults demonstrated in vivo improvement in ATP production in aged skeletal muscle following a single dose — confirming that the preclinical aging-muscle findings translate to human subjects.
Honest Assessment of the Clinical Evidence
SS-31/elamipretide has one of the most mechanistically rigorous and cross-validated research bases of any compound in this catalog. The cardiolipin interaction mechanism has been confirmed by multiple independent research groups using diverse biophysical, biochemical, and genetic approaches. The protein interaction landscape has been mapped by mass spectrometry. The aging biology in mice is replicated across multiple organ systems by multiple laboratories. The cardiolipin-ADP sensitivity mechanistic chain in aged muscle has been directly established.
The clinical evidence is more complex. The Barth syndrome FDA approval reflects the highest regulatory validation, but the primary 12-week endpoints in that trial were not met — the benefit emerged in the open-label extension over 36+ weeks, suggesting a slow-acting structural restoration mechanism. This biology is mechanistically coherent (cardiolipin remodeling is slow) but creates clinical trial design challenges that contributed to some trials’ difficulty demonstrating efficacy on short-duration endpoints.
The EMBRACE STEMI negative result and the MMPOWER-3 challenges illustrate that translating preclinical mitochondrial protection to clinical endpoints in complex heterogeneous human diseases with effort-dependent measurement is pharmacologically difficult even when the mechanism is compelling. Researchers should regard SS-31 as a compound with exceptional mechanistic foundation and regulatory validation in its approved indication, alongside mixed results in broader indications that reflect clinical development challenges rather than mechanistic invalidation.
Current Research Status
SS-31 (elamipretide) received FDA accelerated approval for Barth syndrome in September 2025. Clinical research continues across heart failure, primary mitochondrial myopathy, age-related macular degeneration, kidney disease, and skeletal muscle aging. Academic research continues on the fundamental mechanisms of cardiolipin-targeted mitochondrial protection and the role of mitochondrial dysfunction in aging. The Marcinek and Szeto laboratories remain highly active in characterizing SS-31’s biology in aging models.
Reconstitution Note
SS-31 (elamipretide) is a synthetic tetrapeptide supplied as lyophilized powder. Bacteriostatic water is the standard reconstitution solvent for research use. The compound is water-soluble and dissolves readily in aqueous solution. Protect from light — the Dmt aromatic residue can undergo photodegradation. The 2′,6′-dimethyltyrosine residue also provides some protection against oxidative degradation compared to unmodified tyrosine. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages — Dmt aromatic residue is photosensitive. Avoid repeated freeze-thaw cycles. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of degradation.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the SS-31 product page: https://roguecompounds.com/product/ss-31/